O
ALT icon

OrbiMed’s Altimmune ALT Stock Holding History

OrbiMed’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-100,000
Closed -$422K – 127
2023
Q1 		$422K Buy
+100,000
New +$1.19M 0.01% 122

Other funds holding ALT

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $127M AUM 23.73% 1-Year Est. Return

OrbiMed's ALT Position: Q4 2023 in Review

OrbiMed sold out of Altimmune (ALT) in Q4 2023, closing a stake of 100,000 shares — an estimated $260K sold.

OrbiMed first reported a position in ALT in Q1 2023 and held it in 3 quarters. The position peaked at $353K in Q2 2023. 143 funds tracked by Wall St. Rank hold ALT as of Q4 2023.

  • OrbiMed reported no remaining Altimmune position as of Q4 2023 after selling out during the quarter.
  • OrbiMed sold 100,000 Altimmune shares in Q4 2023, an estimated $260K.
  • OrbiMed first reported a position in Altimmune in Q1 2023 and held it in 3 quarters.
  • OrbiMed's Altimmune position peaked at $353K in Q2 2023.
  • 143 funds tracked by Wall St. Rank held Altimmune as of Q4 2023.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.